Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265953 · ClinicalTrials.gov registry record · NA
Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation
A NA study of Prostate Cancer Prevention, sponsored by Portland VA Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT01265953: Completed NA study of Prostate Cancer Prevention, sponsored by Portland VA Medical Center.
NCT01265953 is a NA study of Prostate Cancer Prevention that has completed, run by Portland VA Medical Center. The registered enrollment target is 98 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01265953, a NA study of Prostate Cancer Prevention, has completed, sponsored by Portland VA Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development. The investigators have found that sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, inhibits histone deacetylase (HDAC) activity in human colorectal and prostate cancer cells.
Primary Outcome
Collection of blood and urine specimens occurred at pre-intervention and post-intervention. Change = post-intervention level minus pre-intervention level
Conditions Studied
Interventions
- DRUG SFN-rich broccoli sprout extract capsules
- DIETARY_SUPPLEMENT Gelatin capsule containing microcrystalline cellulose.
Study Locations (2)
Oregon
- OHSU Knight Cancer Institute - Portland
- Portland VA Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT01265953 record still lists
NCT01265953 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Cancer Prevention appearing as the primary indexed condition, and to 2 interventions - of which SFN-rich broccoli sprout extract capsules is the first listed.
NCT01265953 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT01265953 about?
NCT01265953 is a clinical study titled "Chemoprevention of Prostate Cancer, HDAC Inhibition and DNA Methylation". The objective of the study is to identify mechanisms by which compounds found in cruciferous vegetables alter gene expression via epigenetic modifications (changes in gene expression) and may prevent prostate cancer development. The investigators have found that sulforaphane (SFN), an isothiocyanat...
What is the current status of trial NCT01265953?
This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2011-07. Estimated completion is 2015-12.
What conditions does trial NCT01265953 study?
This clinical trial studies the following conditions: Prostate Cancer Prevention.
What interventions are being tested in trial NCT01265953?
The interventions under investigation include: SFN-rich broccoli sprout extract capsules (DRUG), Gelatin capsule containing microcrystalline cellulose. (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01265953?
This trial is sponsored by Portland VA Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01265953 being conducted?
This trial has 2 study locations across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01265953's enrollment target sits among peer trials
98 922nd of 2000 higher than 1,078 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia